Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23478565 | 0.77 | FUCA1 (0.49) | SIGMAR1FUCA1ACHEALDH1A1MAPT | |
| SCHEMBL15939078 | 0.77 | FUCA1 (0.49) | SIGMAR1FUCA1ACHEALDH1A1MAPT | |
| SCHEMBL1190231 | 0.77 | SIGMAR1 (0.46) | SIGMAR1FUCA1GAAACHECYP3A4 | |
| SCHEMBL4237488 | 0.77 | GAA (0.54) | SIGMAR1FUCA1GAAACHE | |
| SCHEMBL11471422 | 0.75 | SIGMAR1 (0.44) | SIGMAR1FUCA1ALDH1A1MAPT | |
| SCHEMBL4482745 | 0.74 | FUCA1 (0.46) | SIGMAR1FUCA1GAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL11074721 | 0.74 | POLB (0.45) | SIGMAR1FUCA1 | |
| SCHEMBL31325224 | 0.74 | FUCA1 (0.46) | SIGMAR1FUCA1GAAALDH1A1 | |
| SCHEMBL3988127 | 0.74 | SIGMAR1 (0.43) | SIGMAR1FUCA1GAAACHECYP3A4 | |
| SCHEMBL15939000 | 0.74 | GAA (0.44) | SIGMAR1FUCA1GAAACHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | SIGMAR1 317/4885FUCA1 1256/4885GAA 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.